Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2002

View Archived Issues

Positive phase I results for AGI-1096 in prevention of transplant rejection

Amgen files sBLA for Enbrel for improvement of physical function in RA

Theratechnologies adds GLP-1 program to portfolio, signs development agreement with Alza

Final phase I results for Antrin phototherapy in coronary artery disease

Phase I/II interim analysis of Targretin in chronic severe hand dermatitis

Cholestagel MAA filed for primary hypercholesterolemia

NicOx signs exclusive agreement with AstraZeneca for AZD-3582 and other CINODs in Japan

GPI-1485 shows neuroprotective activity in preclinical models of postprostatectomy ED

ISV-401 safe and effective in acute bacterial conjunctivitis

Monoclonal antibodies targeting human BST2

Anti-MRSA cephalosporin and prodrug presented at ICAAC meeting

Potent and broad-spectrum antifungal activity in a series of thiotriazolones

Quinolone-linked oxazolidinones investigated at Morphochem

Korean researchers identify potent parenteral cephalosporin for resistant infections

Phase III interim findings for protease inhibitor GW-433908 discussed in San Diego

Marketing approval granted for first aldosterone blocker in high blood pressure

MGI Pharma/Helsinn seek FDA approval for new CINV therapy

Thrombopoietin agonists prepared and tested at Shionogi

Novartis designs new DPP-IV inhibitors for diabetes mellitus

Toyama researchers identify novel agents for cerebral ischemic disorders

Novel immunosuppressants in early development at Sumitomo

Venantius claims mast cell-stabilizing agents for inflammatory disorders

Novel inhibitors of TNF-alpha and/or IL-1beta production described in Sankyo patent

Long-term survival data for Gliadel Wafer in brain cancer

Allovectin-7 update

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026